Nuformix plc
("Nuformix" or the "Company")
MHRA approval to commence NXP001 Human Pharmacokinetics Studies
Nuformix is developing NXP001 as a treatment for chemotherapy-induced nausea and vomiting ("CINV"). CINV is a large, under-exploited and growing market, which in demographic terms comprises one third of global cancer patients. The primary objective of the study is to investigate the pharmacokinetics and bioavailability of single oral doses of NXP001. Dosing will commence in March 2019, with results expected by end H1 2019.
Dr Dan Gooding, CEO, Nuformix plc, said: "Although expected, receiving approval to advance our first programme into human studies is a major step forward for our Company and our pipeline. The MHRA's decision validates the speed to clinic of our cocrystal approach without the need for further safety data and sets a precedent for our broader pipeline. Completion of these studies will allow us to rapidly progress NXP001 as a cancer supportive care treatment. In addition to triggering the payment of the final
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
Enquiries:
Nuformix plc Dr Dan Gooding, Chief Executive Officer |
+44 (0)1223 627222
|
Optimum Strategic Communications Mary Clark, Supriya Mathur Email: nuformix@optimumcomms.com |
+44 (0) 203 950 9144
|
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the